Seattle Genetics, Takeda lymphoma drug succeeds late-stage trial
June 26, 2017 at 06:58 AM EDT
June 26 (Reuters) - Seattle Genetics Inc and Japan's Takeda Pharmaceutical Co Ltd said on Monday that their drug met the main goal in a late-stage study of helping blood cancer patients live longer without their condition worsening.